Dr.  Nanda’s research interests include identifying novel treatments for the  management of breast cancer, particularly triple-negative disease. She leads  The University of Chicago’s clinical and translational breast cancer research  efforts, and has authored numerous scientific publications and book chapters,  including one of the first reports of immune checkpoint inhibitor therapy for  triple-negative breast cancer. In recognition of her dedication to breast  cancer research, Dr. Nanda has earned numerous awards, including the 2014 NCI  Cancer Clinical Investigator Team Leadership Award.